StephenLouisAronoffMD

Endocrinology • Richardson, TX

Diabetes, Lipid Metabolism

Physician

Join to view full profile

Dr. Aronoff is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Aronoff's full profile

Already have an account?

Office
2400 Lakeside Blvd Ste 130
Richardson, TX 75082
Phone+1 214-774-4475

Fax+1 214-432-5392

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Endocrinology, Diabetes, and Metabolism, 1977 - 1979
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1976 - 1977
University of Texas Southwestern Medical CenterInternship, Internal Medicine, 1972 - 1973
University of Texas Southwestern Medical SchoolClass of 1972

Certifications & Licensure

AZ State Medical License 1980 - Present
TX State Medical License 1972 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Fellow (FACE) American Association of Clinical Endocrinology
Join now to see all

Clinical Trials

A Prospective, Randomized, Parallel Crossover Study Demonstrating Subject Wearability and Usability of the I-Port Injection Port Start of enrollment: 2006 Oct 01
Completed
Not Applicable
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus Start of enrollment: 2010 Jun 18
Completed
Phase 3
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) Start of enrollment: 2012 Jul 01
Completed
Phase 3
Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus Start of enrollment: 2014 Mar 01
Terminated
Phase 2
Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM Start of enrollment: 2015 Sep 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

6 citations
Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes.
Stephen L. Aronoff
Postgraduate Medicine. 2017-02-08
13 citations
Anatabine supplementation decreases thyroglobulin antibodies in patients with chronic lymphocytic autoimmune (Hashimoto's) thyroiditis: a randomized controlled clinica...
Lowell R. Schmeltz, Thomas Blevins, Stephen L. Aronoff, Kerem Ozer, Jonathan D. Leffert
The Journal of Clinical Endocrinology and Metabolism. 2014-01-01
20 citations
Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes.
Thomas Blevins, Jenny Han, Dawn Nicewarner, Steve Chen, Juliana Helena Oliveira
Postgraduate Medicine. 2010-05-01